CARA - Cara Therapeutics, Inc.
| Previous Close | 14.08 |
| Open | 14.05 |
| Bid | 13.86 x 900 |
| Ask | 14.50 x 1200 |
| Day's Range | 13.88 - 14.48 |
| 52 Week Range | 11.46 - 24.30 |
| Volume | 748,834 |
| Avg. Volume | 616,476 |
| Market Cap | 554.228M |
| Beta (3Y Monthly) | 4.06 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.98 |
| Earnings Date | Aug 3, 2017 - Aug 7, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 26.89 |
- ACCESSWIRE•2 days ago
This Unknown Stock With A Market Opportunity Rivaling Cannabis Could Offer Big Upside For Investors
Medical marijuana and its derivatives are gaining rapid acceptance in the U.S. and Canada, and you can see the trend reflected in recent public market action from companies in this space, like Cara Therapeutics (CARA) and CV Sciences Inc. (CVSI) for example. Neurostimulation is also transforming numerous neurological conditions, just like medical marijuana.
- ACCESSWIRE•5 days ago
CBD Industry Growth Sparks Momentum For Marijuana Stocks
CORAL GABLES, FL / ACCESSWIRE / December 11, 2018 / The Brightfield Group, a research firm, recently published a 2018 market overview and analysis on hemp-derived CBD . The summary of their analysis states, ...
- ACCESSWIRE•6 days ago
Alternatives to Watch
HENDERSON, NV / ACCESSWIRE / December 10, 2018 / Below are several companies positioning themselves to be a viable opioid alternative. We are highlighting: Endonovo Therapeutics, Inc. (ENDV), INSYS Therapeutics, ...
- InvestorPlace•13 days ago
The Trade War Could Be a Positive Catalyst for Cara Therapeutics Stock
For all the hype and media attention around the G20 summit in Argentina, it’s clear that U.S.-Chinese trade relations won’t be fixed overnight. One of the topics they have to discuss, interestingly enough, appears to be America’s opioid crisis. As a result, America’s opioid crisis will become more prominent in news coverage, potentially providing a positive catalyst for Cara Therapeutics (NASDAQ:CARA) and CARA stock.
- Motley Fool•14 days ago
Why Cara Therapeutics Is Up 50% in 2018
Three key reasons behind this clinical-stage biotech's impressive year-to-date performance.
- ACCESSWIRE•25 days ago
Opioid Alternatives Could Make Investors Major Gains
HENDERSON, NV / ACCESSWIRE / November 21, 2018 / Moderna and Synthorx's huge IPOs show biotech point to a strong biotech sector that should continue a bull run heading into the new year. CBD based biotechs ...
- Market Realist•27 days ago
MedMen’s Territory Expansion: The Recent Agreements
MedMen (MMNFF) has entered into agreements with different companies to expand its footprint. We outline a few of the recent agreements below.
- Market Realist•last month
Curaleaf Opens Medical Marijuana Dispensary in Tallahassee
Curaleaf Holdings (LDVTF) is one of the leading cannabis operators in the United States. On November 16, Curaleaf Holdings announced that the company opened Tallahassee’s largest medical marijuana dispensary in the Midtown area. The above chart lists the details about Curaleaf’s new dispensary in Tallahassee.
- Benzinga•last month
12 NYSE- And NASDAQ-Listed Stocks With Cannabis Exposure
For investors who are seeking exposure to the cannabis industry but consider pure-play companies too risky, there are many other interesting investment opportunities. Pharma and biotech companies have ...
- Market Realist•last month
Corbus Pharmaceuticals Holdings’ Performance in 2018
Corbus Pharmaceuticals Holdings (CRBP) is a clinical-stage pharmaceutical company focused on developing and commercializing products for rare, life-threatening inflammatory fibrotic diseases.
- Market Realist•last month
Analyzing 22nd Century Group’s Year-to-Date Performance
22nd Century Group (XXII) is a plant biotechnology company that’s focused on developing technologies to manage the nicotine content in tobacco plants and the cannabinoids in cannabis plants using gene editing and plant breeding technologies.
- GlobeNewswire•last month
Research Report Identifies DXP Enterprises, Diebold Nixdorf, Fitbit, Nevro, Plains All American Pipeline, and Cara Therapeutics with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, Nov. 12, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Market Realist•last month
How Has Cara Therapeutics’ 2018 Performance Shaken Out?
Cara Therapeutics (CARA) is a clinical-stage biotechnology company developing new chemical entities for managing pain and pruritus. Cara Therapeutics reported EPS of -$0.52 on revenue of $2.87 million in the second quarter.
- Thomson Reuters StreetEvents•last month
Edited Transcript of CARA earnings conference call or presentation 6-Nov-18 9:30pm GMT
Q3 2018 Cara Therapeutics Inc Earnings Call
- Market Realist•last month
A Closer Look at Insys Therapeutics’ Performance Year-to-Date
Insys Therapeutics (INSY) is among the specialty pharmaceutical companies that focus on developing cannabinoids and sprays.
- Market Realist•last month
How Marijuana-Focused Biotech Companies Have Performed in 2018
Exploring Marijuana-Focused Biotech Companies' 2018 PerformancesMarijuana-focused biotech companies
- GlobeNewswire•last month
Cara Therapeutics to Present at November Investor Conferences
STAMFORD, Conn., Nov. 08, 2018 -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to.
- Zacks•last month
Cara Therapeutics (CARA) Reports Q3 Loss, Tops Revenue Estimates
Cara (CARA) delivered earnings and revenue surprises of -10.87% and 7.34%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•last month
Cara: 3Q Earnings Snapshot
On a per-share basis, the Stamford, Connecticut-based company said it had a loss of 51 cents. The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...
- GlobeNewswire•last month
Cara Therapeutics Reports Third Quarter 2018 Financial Results
– Conference call today at 4:30 p.m. ET – STAMFORD, Conn., Nov. 06, 2018 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing.
- Motley Fool•last month
3 Top Small-Cap Stocks to Buy Right Now
Big gains sometimes come in small packages.
- ACCESSWIRE•last month
Cannabis and Biotech Stocks That Could Bounce
HENDERSON, NV / ACCESSWIRE / November 1, 2018 / A stem cell play we like a lot is BioRestorative Therapies, Inc.,(BRTX) a life sciences company focused on stem cell-based therapies. Defined Health is a business development and strategy consulting firm that has worked with many of the leading companies in the pharmaceutical, biotech and healthcare industries for over 25 years. BRTX plans to use the results of the review to further refine its planned activities around BRTX-100, including potential licensing, co-development and commercialization activities.
- GlobeNewswire•2 months ago
Cara Therapeutics to Announce Third Quarter 2018 Financial Results on November 6, 2018
STAMFORD, Conn., Oct. 30, 2018 -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to.
- Motley Fool•2 months ago
Better Buy: Cara Therapeutics, Inc. vs. Scotts Miracle-Gro Company
Which stock wins in a matchup between a high-flying clinical-stage biotech and a leading supplier to the marijuana industry?
- Investopedia•2 months ago
Medical Cannabis Stocks Vs. Recreational Cannabis Stocks: Which Ones Should You Invest In?
Broadly the industry is divided into two markets: the market for medical marijuana and the one for recreational marijuana. According to a report released by research firm ArcView Market Research and BDS analytics, the overall share of the medical marijuana industry slid from 100% in 2013 to 71% in 2017. As of this writing, nine states have completely legalized recreational marijuana.) By 2027, medical marijuana will be just 33% of the overall market states ArcView.
